The California Department of Public Health is advising all facilities to take the following actions based on an urgent message from the Food and Drug Administration (FDA):
Immediately discontinue use of Curlin IV Sets with the following REF (catalog) and lot numbers, which were sold and distributed between December 2011 and May 2012:
REF Codes (found in the top right hand corner of the administration set packaging):
340-4114 | ā340-4126 | ā340-4128-V | ā340-4130-V | ā340-4137 | ā340-4165 | ā340-4173 |
ā340-4115 | ā340-4128 | ā340-4130 | ā340-4133 | ā340-4144 | ā340-4166 | ā340-4176 |
Lot Numbers (found in the lower right hand corner of the administration set packaging):
CF1127990 | āCF1132291 | āCF1200291 | āCF1201890 | āCF1204092 | āCF1206092 |
āCF1127991 | āCF1133490 | āCF1200292 | āCF1201891 | āCF1204093 | āCF1206890 |
āCF1127992 | āCF1133491 | āCF1200293 | āCF1201892 | āCF1204690 | āCF1206891 |
āCF1129990 | āCF1134390 | āCF1200294 | āCF1201893 | āCF1204691 | āCF1206893 |
āCF1130190 | āCF1134391 | āCF1200490 | āCF1202590 | āCF1204692 | āCF1207590 |
āCF1130690 | āCF1134392 | āCF1200491 | āCF1202591 | āCF1205490 | āCF1207591 |
āCF1130691 | āCF1134393 | āCF1200492 | āCF1202592 | āCF1205491 | āCF1207592 |
āCF1130692 | āCF1134990 | āCF1200493 | āCF1203390 | āCF1205492 | āCF1207593 |
āCF1130693 | āCF1135490 | āCF1200494 | āCF1203391 | āCF1205493 | āCF1208090 |
āCF1131190 | āCF1135491 | āCF1201190 | āCF1203392 | āCF1205990 | āCF1208091 |
āCF1131191 | āCF1135492 | āCF1201191 | āCF1204090 | āCF1206090 | āCF1208092 |
āCF1132290 | āCF1200290 | āCF1201192 | āCF1204091 | āCF1206091 | āCF1209091 |
The FDA advises that Moog Medical Devices Group (MMDG) has voluntarily issued a recall for these lots of Curlin IV Administration Sets, which have the potential to cause serious injury or death due to blood loss, under-delivery of prescribed medication/fluid, or a potential delay in therapy. The recall was initiated as a result of a customer-discovered
reverse pump segment. To date, customer complaints have identified three (3) out of 544,900 suspect sets manufactured for the United States. Despite the potential for reverse flow when using an affected set, MMDG has not received any reports of injury or death as a result of this issue. MMDG has identified and corrected the root cause by immediately initiating a supplier corrective action request and implementing additional preventative measures.
MMDG is working with the FDA to coordinate recall activities. Direct customers and distributors will be notified of the process for obtaining replacement administration sets by MMDG. For additional questions, contact Moog Customer Advocacy at (800) 970-2337.
Healthcare professionals and patients are encouraged to report any adverse events or side effects related to the use of these products to the FDA's MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
Online: (https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm)
Regular mail: MedWatch
5600 Fishers Lane
Rockville, MD 20852-9787
Fax: 1-800-FDA-0178
For mail or fax reporting, please use FDA form 3500, available at the FDA website:
(https://www.fda.gov/safety/medwatch/howtoreport/downloadforms/default.htm) or by request by calling 1-800-332-1088.
Thank you for your prompt attention to this matter.
Sincerely,
Original Signed By Debby Rogers
Debby Rogers, RN, MS, FAEN
Deputy Director
Center for Health Care Quality